A case-control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer

Chinese Journal of Lung Cancer

Volumn 8, Issue 2, 2005, Pages 89-94

  Guo, Zhanlin ^a   Zhou, Qinghua ^a   Zhu, Wen ^a   Li, Dairong ^a   Yuan, Tianzhu ^a   Wang, Yanping ^a   Chen, Xiaohe ^a   Liu, Lunxu ^a   Wu, Zhu ^a   Yang, Junjie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cytochrome P450 2D6; Genetic polymorphism; Pulmonary neoplasms

Indexed keywords

CYTOCHROME P450 2D6; CYTOSINE; THYMINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; XENOBIOTIC METABOLISM;

EID: 20244370041     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian-population: allele frequencies and phenotypic consequences. Am J Hum Genet, 1997, 60(2): 284-295.
2. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 1993, 3(3): 256-263.
3. Lee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol, 1994, 37 (6): 605-607.
4. Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res, 1999, 444(2): 441-449. Erratum in: Mutat Res, 2000, 464(2): 311.
5. Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res, 1999, 444(2): 441-449. Erratum in: Mutat Res, 2000, 464(2): 311.
6. Ji L, Pan S, Wu J, et al. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl), 2002, 115(12): 1780-1784.
7. Armstrong M, Fairbrother K, Idle JR, et al. The Cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics,1994, 4(2): 73-81.
8. Roh HK, Dahl ML, Johansson I, et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 1996, 6(5): 441-447.
9. 6 Ch gene in Chinese subjects. Chin J Birth Health Heredity, 1998, 6(6): 16-17.
10. Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res,1998, 15(4): 517-524.
11. Li DR, Zhou QH. Advance in studies on genetic susceptibility of lung cancer. Chin J Lung Cancer, 2003, 6(2): 158-162.
12. Ayesh R, Idle JR, Ritchie JC, et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 1984, 312(5990): 169-170.
13. Shaw GL, Falk RT, Deslauriers J, et al. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 1995, 4 (1): 41-48.
14. Gu YF, Zhang SC, Lai BT, et al. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibity. Chin J Lung Cancer, 2003, 7(2): 112-117.
15. Stucker I, Cosme J, Laurent P, et al. CYP2D6 genotype and lung, cancer risk according to histologie type and tobacco exposure. Carcinogenesis, 1995, 16(11): 2759-2764.